GT Biopharma is trading 9.84% down at $5.50 after-hours; the reason for the decline remains unconfirmed. - Shares closed at $6.10 on October 2, 2026, and recent closes show a continued slide. - The company’s press-release page lists no October 2 announcement; its latest listed release is dated September 15. - Major market indexes were higher, and available evidence does not point to broad-market weakness as the explanation.